Alentis Therapeutics Ag

This study tests a new drug called ALE.F02 in people with ANCA-associated vasculitis, an autoimmune disease that attacks small blood vessels and often damages the kidneys. The goal is to see if adding ALE.F02 to standard treatment can protect kidney function and is safe. About 80…

This study tests a new drug called ALE.P02 in people with advanced squamous cell cancers of the lung, head and neck, cervix, or esophagus. The drug is designed to target a protein called Claudin-1 found on these cancer cells. The main goals are to check the drug's safety, find th…

This study tests a new drug called ALE.P03 in adults with advanced cancers (cervical, lung, colorectal, bile duct, or bladder) that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to target a protein called Claudin-1 found on these tumor…